Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

Rhea-AI Summary

Schrödinger (Nasdaq: SDGR) announced that its CEO, Ramy Farid, Ph.D., will participate in the BMO BioPharma Spotlight Series on Technology-Enabled Drug Discovery. The virtual panel is scheduled for Friday, April 16, at 10:00 a.m. ET. An on-demand webcast will be available on Schrödinger's website under the 'News & Events' section and will remain accessible for about seven days. Schrödinger is revolutionizing drug and material discovery through its physics-based software platform, which enhances the speed and cost-effectiveness of developing novel therapeutics.

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery. The panel will take place virtually on Friday, April 16, at 10:00 a.m. ET.

The “on demand” webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately 7 days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005031/en/

FAQ

When is Ramy Farid participating in the BMO BioPharma Spotlight Series for SDGR?

Ramy Farid will participate on Friday, April 16, at 10:00 a.m. ET.

How can I access the BMO BioPharma Spotlight Series webcast for SDGR?

The webcast can be accessed on Schrödinger's website under 'News & Events' and will be available for about seven days.

What is the focus of the BMO BioPharma Spotlight Series involving SDGR?

The focus is on Technology-Enabled Drug Discovery.

What is Schrödinger's software platform known for?

Schrödinger's software platform is known for transforming drug discovery and material development to be faster and less expensive.

How many employees does Schrödinger have?

Schrödinger has over 450 employees.